Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Coronary Artery Disease: HELP
Articles from Philadelphia
Based on 373 articles published since 2010
||||

These are the 373 published articles about Coronary Artery Disease that originated from Philadelphia during 2010-2020.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15
1 Guideline ACR Appropriateness Criteria 2018

Anonymous7160967 / Shah, Amar B / Kirsch, Jacobo / Bolen, Michael A / Batlle, Juan C / Brown, Richard K J / Eberhardt, Robert T / Hurwitz, Lynne M / Inacio, Joao R / Jin, Jill O / Krishnamurthy, Rajesh / Leipsic, Jonathon A / Rajiah, Prabhakar / Singh, Satinder P / White, Richard D / Zimmerman, Stefan L / Abbara, Suhny. ·Westchester Medical Center, Valhalla, New York. Electronic address: ashah27@northwell.edu. · Panel Chair, Cleveland Clinic Florida, Weston, Florida. · Panel Vice-Chair, Cleveland Clinic, Cleveland, Ohio. · Miami Cardiac and Vascular Institute and Baptist Health of South Florida, Miami, Florida. · University of Michigan Health System, Ann Arbor, Michigan. · Boston University School of Medicine, Boston, Massachusetts; American College of Cardiology. · Duke University Medical Center, Durham, North Carolina. · The Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Canada. · Northwestern University Feinberg School of Medicine, Chicago, Illinois; American College of Physicians. · Nationwide Children's Hospital, Columbus, Ohio. · St. Paul's Hospital, Vancouver, British Columbia, Canada. · UT Southwestern Medical Center, Dallas, Texas. · University of Alabama at Birmingham, Birmingham, Alabama. · The Ohio State University Wexner Medical Center, Columbus, Ohio. · Johns Hopkins Medical Institute, Baltimore, Maryland. · Specialty Chair, UT Southwestern Medical Center, Dallas, Texas. ·J Am Coll Radiol · Pubmed #30392597.

ABSTRACT: Chronic chest pain (CCP) of a cardiac etiology is a common clinical problem. The diagnosis and classification of the case of chest pain has rapidly evolved providing the clinician with multiple cardiac imaging strategies. Though scintigraphy and rest echocardiography remain as appropriate imaging tools in the diagnostic evaluation, new technology is available. Current evidence supports the use of alternative imaging tests such as coronary computed tomography angiography (CCTA), cardiac MRI (CMRI), or Rb-82 PET/CT. Since multiple imaging modalities are available to the clinician, the most appropriate noninvasive imaging strategy will be based upon the patient's clinical presentation and clinical status. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment.

2 Guideline Risk Assessment for Cardiovascular Disease With Nontraditional Risk Factors: US Preventive Services Task Force Recommendation Statement. 2018

Anonymous4820954 / Curry, Susan J / Krist, Alex H / Owens, Douglas K / Barry, Michael J / Caughey, Aaron B / Davidson, Karina W / Doubeni, Chyke A / Epling, John W / Kemper, Alex R / Kubik, Martha / Landefeld, C Seth / Mangione, Carol M / Silverstein, Michael / Simon, Melissa A / Tseng, Chien-Wen / Wong, John B. ·University of Iowa, Iowa City. · Fairfax Family Practice Residency, Fairfax, Virginia. · Virginia Commonwealth University, Richmond. · Veterans Affairs Palo Alto Health Care System, Palo Alto, California. · Stanford University, Stanford, California. · Harvard Medical School, Boston, Massachusetts. · Oregon Health & Science University, Portland. · Columbia University, New York, New York. · University of Pennsylvania, Philadelphia. · Virginia Tech Carilion School of Medicine, Roanoke. · Nationwide Children's Hospital, Columbus, Ohio. · Temple University, Philadelphia, Pennsylvania. · University of Alabama at Birmingham. · University of California, Los Angeles. · Boston University, Boston, Massachusetts. · Northwestern University, Evanston, Illinois. · University of Hawaii, Honolulu. · Pacific Health Research and Education Institute, Honolulu, Hawaii. · Tufts University, Medford, Massachusetts. ·JAMA · Pubmed #29998297.

ABSTRACT: Importance: Cardiovascular disease (CVD) is the most common cause of death among adults in the United States. Treatment to prevent CVD events by modifying risk factors is currently informed by the Framingham Risk Score, the Pooled Cohort Equations, or similar CVD risk assessment models. If current CVD risk assessment models could be improved by adding more risk factors, treatment might be better targeted, thereby maximizing the benefits and minimizing the harms. Objective: To update the 2009 US Preventive Services Task Force (USPSTF) recommendation on using nontraditional risk factors in coronary heart disease risk assessment. Evidence Review: The USPSTF reviewed the evidence on using nontraditional risk factors in CVD risk assessment, focusing on the ankle-brachial index (ABI), high-sensitivity C-reactive protein (hsCRP) level, and coronary artery calcium (CAC) score; the health benefits and harms of CVD risk assessment and treatment guided by nontraditional risk factors combined with the Framingham Risk Score or Pooled Cohort Equations compared with using either risk assessment model alone; and whether adding nontraditional risk factors to existing CVD risk assessment models improves measures of calibration, discrimination, and risk reclassification. Findings: The USPSTF found adequate evidence that adding the ABI, hsCRP level, and CAC score to existing CVD risk assessment models results in small improvements in discrimination and risk reclassification; however, the clinical meaning of these changes is largely unknown. Evidence on adding the ABI, hsCRP level, and CAC score to the Pooled Cohort Equations is limited. The USPSTF found inadequate evidence to assess whether treatment decisions guided by the ABI, hsCRP level, or CAC score, in addition to risk factors in existing CVD risk assessment models, leads to reduced incidence of CVD events or mortality. The USPSTF found adequate evidence to conceptually bound the harms of early detection and interventions as small. The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of using the ABI, hsCRP level, or CAC score in risk assessment for CVD in asymptomatic adults to prevent CVD events. Conclusions and Recommendation: The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of adding the ABI, hsCRP level, or CAC score to traditional risk assessment for CVD in asymptomatic adults to prevent CVD events. (I statement).

3 Guideline ACR Appropriateness Criteria 2017

Anonymous3040905 / Akers, Scott R / Panchal, Vandan / Ho, Vincent B / Beache, Garth M / Brown, Richard K J / Ghoshhajra, Brian B / Greenberg, S Bruce / Hsu, Joe Y / Kicska, Gregory A / Min, James K / Stillman, Arthur E / Stojanovska, Jadranka / Abbara, Suhny / Jacobs, Jill E. ·Principal Author, VA Medical Center, Philadelphia, Pennsylvania. Electronic address: akerssco@me.com. · Research Author, Internal Medicine Resident, Henry Ford Allegiance Health, Jackson, Michigan. · Panel Vice-Chair, Uniformed Services University of the Health Sciences, Bethesda, Maryland. · University of Louisville School of Medicine, Louisville, Kentucky. · University Hospital, Ann Arbor, Michigan. · Massachusetts General Hospital, Boston, Massachusetts. · Arkansas Children's Hospital, Little Rock, Arkansas. · Kaiser Permanente, Los Angeles, California. · University of Washington, Seattle, Washington. · Cedars Sinai Medical Center, Los Angeles, California; American College of Cardiology. · Emory University Hospital, Atlanta, Georgia. · University of Michigan Health System, Ann Arbor, Michigan. · Specialty Chair, UT Southwestern Medical Center, Dallas, Texas. · Panel Chair, New York University Medical Center, New York, New York. ·J Am Coll Radiol · Pubmed #28473096.

ABSTRACT: In patients with chronic chest pain in the setting of high probability of coronary artery disease (CAD), imaging has major and diverse roles. First, imaging is valuable in determining and documenting the presence, extent, and severity of myocardial ischemia, hibernation, scarring, and/or the presence, site, and severity of obstructive coronary lesions. Second, imaging findings are important in determining the course of management of patients with suspected chronic myocardial ischemia and better defining those patients best suited for medical therapy, angioplasty/stenting, or surgery. Third, imaging is also necessary to determine the long-term prognosis and likely benefit from various therapeutic options by evaluating ventricular function, diastolic relaxation, and end-systolic volume. Imaging studies are also required to demonstrate other abnormalities, such as congenital/acquired coronary anomalies and severe left ventricular hypertrophy, that can produce angina in the absence of symptomatic coronary obstructive disease due to atherosclerosis. Clinical risk assessment is necessary to determine the pretest probability of CAD. Multiple methods are available to categorize patients as low, medium, or high risk for developing CAD. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment.

4 Guideline The Rationale for Performance of Coronary Angiography and Stenting Before Transcatheter Aortic Valve Replacement: From the Interventional Section Leadership Council of the American College of Cardiology. 2016

Ramee, Stephen / Anwaruddin, Saif / Kumar, Gautam / Piana, Robert N / Babaliaros, Vasilis / Rab, Tanveer / Klein, Lloyd W / Anonymous10330889 / Anonymous10340889. ·Ochsner Medical Center, New Orleans, Louisiana. · Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania. · Emory University/Atlanta VA Medical Center, Atlanta, Georgia. · Vanderbilt University Medical Center, Nashville, Tennessee. · Emory University School of Medicine, Atlanta, Georgia. · Rush Medical College, Chicago, Illinois. Electronic address: lloydklein@comcast.net. ·JACC Cardiovasc Interv · Pubmed #27931592.

ABSTRACT: Transcatheter aortic valve replacement (TAVR) is an effective, nonsurgical treatment option for patients with severe aortic stenosis. The optimal treatment strategy for treating concomitant coronary artery disease (CAD) has not been tested prospectively in a randomized clinical trial. Nevertheless, it is standard practice in the United States to perform coronary angiography and percutaneous coronary intervention for significant CAD at least 1 month before TAVR. All existing clinical trials were designed using this strategy. Therefore, it is wrong to extrapolate current American College of Cardiology/American Heart Association Appropriate Use Criteria against invasive procedures in asymptomatic patients to the TAVR population when evaluating the quality of care by cardiologists or hospitals. In this statement from the Interventional Section Leadership Council of the ACC, it is recommended that percutaneous coronary intervention should be considered in all patients with significant proximal coronary stenosis in major coronary arteries before TAVR, even though the indication is not covered in current guidelines.

5 Guideline SCAI expert consensus statement: 2016 best practices in the cardiac catheterization laboratory: (Endorsed by the cardiological society of india, and sociedad Latino Americana de Cardiologia intervencionista; Affirmation of value by the Canadian Association of interventional cardiology-Association canadienne de cardiologie d'intervention). 2016

Naidu, Srihari S / Aronow, Herbert D / Box, Lyndon C / Duffy, Peter L / Kolansky, Daniel M / Kupfer, Joel M / Latif, Faisal / Mulukutla, Suresh R / Rao, Sunil V / Swaminathan, Rajesh V / Blankenship, James C. ·Division of Cardiology, Winthrop University Hospital, Mineola, New York. ssnaidu@winthrop.org. · Warren Alpert Medical School of Brown University, Cardiovascular Institute, Providence, RI. · West Valley Medical Center, Caldwell, ID. · FirstHealth of the Carolinas, Pinehurst, NC. · Cardiovascular Medicine Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. · University of Illinois School of Medicine-Peoria, Peoria, IL. · University of Oklahoma and VA Medical Center, Oklahoma City, OK. · University of Pittsburgh and VA Pittsburgh Healthcare System, Pittsburgh, PA. · Duke University Medical Center, Durham, NC. · Weill Cornell Medical College, New York-Presbyterian Hospital, Greenberg Division of Cardiology, New York, NY. · Geisinger Medical Center, Danville, PA. ·Catheter Cardiovasc Interv · Pubmed #27137680.

ABSTRACT: -- No abstract --

6 Editorial Paradigm Shifts in the Treatment of Stable Ischemic Heart Disease. 2019

Adusumalli, Srinath / Giri, Jay. ·Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania, Philadelphia. Cardiovascular Outcomes, Quality, and Evaluative Research Center and Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia. ·Circ Cardiovasc Qual Outcomes · Pubmed #30773026.

ABSTRACT: -- No abstract --

7 Editorial Apolipoprotein A-I Infusion Therapies for Coronary Disease: Two Outs in the Ninth Inning and Swinging for the Fences. 2018

Rader, Daniel J. ·Department of Genetics, Institute for Translational Medicine and Therapeutics, Perelman School of Medicine at University of Pennsylvania, Philadelphia. ·JAMA Cardiol · Pubmed #30046821.

ABSTRACT: -- No abstract --

8 Editorial Percutaneous Coronary Intervention and the Obesity Paradox: Fat Chance. 2018

Savage, Michael P / Fischman, David L. ·Department of Medicine (Cardiology), Thomas Jefferson University Hospital, Philadelphia, Pennsylvania. Electronic address: Michael.savage@jefferson.edu. · Department of Medicine (Cardiology), Thomas Jefferson University Hospital, Philadelphia, Pennsylvania. ·JACC Cardiovasc Interv · Pubmed #29248406.

ABSTRACT: -- No abstract --

9 Editorial Intracoronary Imaging, Reverse Cholesterol Transport, and Transcriptomics: Precision Medicine in CAD? 2017

Chhatriwalla, Adnan K / Rader, Daniel J. ·Division of Cardiology, Saint Luke's Mid America Heart Institute, Kansas City, Missouri; Department of Medicine, University of Missouri-Kansas City, Kansas City, Missouri. Electronic address: achhatriwalla@saint-lukes.org. · Departments of Genetics, Medicine, and Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. ·J Am Coll Cardiol · Pubmed #28183507.

ABSTRACT: -- No abstract --

10 Editorial Coronary Bypass Surgery Versus Percutaneous Coronary Intervention in Left Main and Multivessel Disease: Incremental Data-How Do We Apply It? 2016

Hirshfeld, John W / Fiorilli, Paul N. ·Cardiovascular Medicine Division, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: hirshfel@mail.med.upenn.edu. · Cardiovascular Medicine Division, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania. ·JACC Cardiovasc Interv · Pubmed #28007200.

ABSTRACT: -- No abstract --

11 Editorial SCAI position statement concerning coverage policies for percutaneous coronary interventions based on the appropriate use criteria. 2016

Klein, Lloyd W / Blankenship, James C / Kolansky, Daniel M / Dean, Larry S / Naidu, Srihari S / Chambers, Charles E / Duffy, Peter L / Anonymous2130861. ·Rush Medical College, Chicago, IL. · Geisinger Medical Center, Danville, PA. · University of Pennsylvania School of Medicine, Philadelphia, PA. · University of Washington, Seattle, WA. · Winthrop University Hospital, Mineola, NY. · Hershey Medical Center, Hershey, PA. · FirstHealth of the Carolinas, Reid Heart Center, Pinehurst, NC. ·Catheter Cardiovasc Interv · Pubmed #26968441.

ABSTRACT: -- No abstract --

12 Editorial Hybrid coronary revascularization: Ready for prime time, but who should star? 2016

Hiesinger, William / Atluri, Pavan. ·Division of Cardiovascular Surgery, Department of Surgery, University of Pennsylvania School of Medicine, Philadelphia, Pa. · Division of Cardiovascular Surgery, Department of Surgery, University of Pennsylvania School of Medicine, Philadelphia, Pa. Electronic address: pavan.atluri@uphs.upenn.edu. ·J Thorac Cardiovasc Surg · Pubmed #26809426.

ABSTRACT: -- No abstract --

13 Editorial A Potential Role for Aromatase Levels in Coronary Heart Disease. 2016

Ehrlich, Garth D. ·1 Department of Microbiology and Immunology, Center for Genomic Sciences and Center for Advanced Microbial Processing, Institute of Molecular Medicine and Infectious Diseases, Drexel University College of Medicine, Philadelphia, PA. · 2 Department of Otolaryngology-Head and Neck Surgery, Center for Genomic Sciences and Center for Advanced Microbial Processing, Institute of Molecular Medicine and Infectious Diseases, Drexel University College of Medicine, Philadelphia, PA. ·Genet Test Mol Biomarkers · Pubmed #26780325.

ABSTRACT: -- No abstract --

14 Editorial IRF2BP2: A New Player at the Crossroads of Inflammation and Lipid Metabolism. 2015

Zhang, Hanrui / Reilly, Muredach P. ·From the Department of Medicine, Cardiovascular Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia. zhangha@mail.med.upenn.edu muredach@mail.med.upenn.edu. ·Circ Res · Pubmed #26405180.

ABSTRACT: -- No abstract --

15 Editorial Pediatric Heart Transplant Recipients and Cardiac Allograft Vasculopathy: The Importance of Hemodynamics. 2015

Eisen, Howard J. ·Division of Cardiology, Drexel University College of Medicine, Philadelphia, Pennsylvania. Electronic address: heisen@drexelmed.edu. ·J Am Coll Cardiol · Pubmed #26227195.

ABSTRACT: -- No abstract --

16 Editorial Reducing the burden of disease and death from familial hypercholesterolemia: a call to action. 2014

Knowles, Joshua W / O'Brien, Emily C / Greendale, Karen / Wilemon, Katherine / Genest, Jacques / Sperling, Laurence S / Neal, William A / Rader, Daniel J / Khoury, Muin J. ·Stanford University School of Medicine and Cardiovascular Institute, Stanford, CA; The FH Foundation, South Pasadena, CA. · Duke Clinical Research Institute, Durham, NC. Electronic address: emily.obrien@duke.edu. · The FH Foundation, South Pasadena, CA. · McGill University, Montreal, Canada. · Emory University School of Medicine, Atlanta, GA. · West Virginia University, Morgantown, WV. · University of Pennsylvania, Philadelphia, PA. · Office of Public Health Genomics, Centers for Disease Control & Prevention, Atlanta, GA. ·Am Heart J · Pubmed #25458642.

ABSTRACT: Familial hypercholesterolemia (FH) is a genetic disease characterized by substantial elevations of low-density lipoprotein cholesterol, unrelated to diet or lifestyle. Untreated FH patients have 20 times the risk of developing coronary artery disease, compared with the general population. Estimates indicate that as many as 1 in 500 people of all ethnicities and 1 in 250 people of Northern European descent may have FH; nevertheless, the condition remains largely undiagnosed. In the United States alone, perhaps as little as 1% of FH patients have been diagnosed. Consequently, there are potentially millions of children and adults worldwide who are unaware that they have a life-threatening condition. In countries like the Netherlands, the United Kingdom, and Spain, cascade screening programs have led to dramatic improvements in FH case identification. Given that there are currently no systematic approaches in the United States to identify FH patients or affected relatives, the patient-centric nonprofit FH Foundation convened a national FH Summit in 2013, where participants issued a "call to action" to health care providers, professional organizations, public health programs, patient advocacy groups, and FH experts, in order to bring greater attention to this potentially deadly, but (with proper diagnosis) eminently treatable, condition.

17 Editorial Optimal blood pressure targets in older adults: how low is low enough? 2014

Gradman, Alan H. ·Temple University School of Medicine (Clinical Campus), Pittsburgh, Pennsylvania. Electronic address: gradmana@temple.edu. ·J Am Coll Cardiol · Pubmed #25145523.

ABSTRACT: -- No abstract --

18 Editorial Apolipoprotein A-I and cholesterol efflux: the good, the bad, and the modified. 2014

Javaheri, Ali / Rader, Daniel J. ·From the Department of Medicine and Cardiovascular Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia. · From the Department of Medicine and Cardiovascular Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia. rader@mail.med.upenn.edu. ·Circ Res · Pubmed #24855198.

ABSTRACT: -- No abstract --

19 Review Exercise Recommendations for the Athlete With Coronary Artery Disease. 2019

Rao, Prashant / Shipon, David. ·Beth Israel Deaconess Medical Center, Boston, MA, USA. · Harvard Medical School, Boston, MA, USA. · Thomas Jefferson University Hospital, Philadelphia, PA, USA. David.m.shipon@jefferson.edu. ·Curr Treat Options Cardiovasc Med · Pubmed #31820188.

ABSTRACT: PURPOSE OF THE REVIEW: We provide a framework for formulating exercise prescriptions for those with CAD in order to achieve the "optimal" dose of exercise for each individual. RECENT FINDINGS: Multiple epidemiological studies demonstrate that exercise is inversely associated with atherosclerotic coronary artery disease (CAD), yet the risk of an acute coronary event is transiently elevated during vigorous exercise. In turn, CAD is the most common cause of exercise-related sudden cardiac death (SCD) in older athletes. When prescribing exercise recommendations for athletes with CAD, we should maintain equipoise between the benefits derived from sports participation and the risk of an adverse cardiac event. Athletes are not immune from atherosclerotic CAD, and we should perform risk assessments regardless of physical and athletic prowess. Cardiopulmonary exercise testing may be a useful tool to develop individualized exercise regimens for athletes with CAD.

20 Review Angiopoietin-Like 3: From Discovery to Therapeutic Gene Editing. 2019

Wang, Xiao / Musunuru, Kiran. ·Department of Medicine and Department of Genetics, Cardiovascular Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania. ·JACC Basic Transl Sci · Pubmed #31709322.

ABSTRACT: Hyperlipidemia is a major causal risk factor for atherosclerosis and coronary heart disease (CHD). Angiopoietin-like 3 (ANGPTL3) has emerged as a promising molecular target to reduce CHD risk due to its regulation of all 3 major lipid traits: low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides. Here, the authors review the discovery of ANGPTL3, the role of ANGPTL3 in lipoprotein metabolism, and the genetic association between naturally occurring ANGPTL3 loss-of-function mutations and CHD. In light of the favorable consequences of ANGPTL3 deficiency, various therapeutic strategies to target ANGPTL3 are currently in development, including a monoclonal antibody, an antisense oligonucleotide, and gene editing.

21 Review Evolving Role of PET in Detecting and Characterizing Atherosclerosis. 2019

Høilund-Carlsen, Poul Flemming / Moghbel, Mateen C / Gerke, Oke / Alavi, Abass. ·Department of Nuclear Medicine, Odense University Hospital, J. B. Winsløws Vej 4, 5000 Odense C, Denmark; Department of Clinical Research, University of Southern Denmark, Winsløwparken 19, 3. salOdense C - DK-5000, Denmark. Electronic address: pfhc@rsyd.dk. · Department of Radiology, Stanford University Medical Center, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA 94305-5105, USA. · Department of Nuclear Medicine, Odense University Hospital, J. B. Winsløws Vej 4, 5000 Odense C, Denmark. · Department of Radiology, Hospital of University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA. ·PET Clin · Pubmed #30826018.

ABSTRACT: Cardiovascular molecular imaging has focused on assessing myocardial perfusion and ventricular ejection fraction. These modalities target late downstream effects of the atherosclerotic disease process; this calls for a change of focus toward methods that can detect early arterial wall changes before macrocalcifications become visible on computed tomography angiography and provide a better understanding of the disease process. We summarize current knowledge on PET in atherosclerosis and highlight pertinent questions relating to the early detection of atherosclerosis. The future of PET in atherosclerosis may be early individualized quantification of the arteriosclerotic disease burden rather than exploration of features of individual arterial plaques.

22 Review Racial Disparities in the Cardiac Computed Tomography Assessment of Coronary Artery Disease: Does Gender Matter. 2019

El-Menyar, Ayman / Abuzaid, Ahmed / Elbadawi, Ayman / McIntyre, Matthew / Latifi, Rifat. ·From the Clinical Medicine, Weill Cornell Medical College, Doha, Qatar. · Division of Cardiology, Department of Medicine, Westchester Medical Center, Valhalla, NY. · Cardiology Department, Sidney Kimmel Medical College at Thomas Jefferson University/Christiana Care Health System, Newark, DE. · Department of Internal Medicine, Rochester General Hospital, Rochester, NY. · New York Medical College, Valhalla, NY. · Department of Surgery, Westchester Medical Center, Valhalla, NY. ·Cardiol Rev · Pubmed #30520779.

ABSTRACT: Coronary heart disease (CHD) represents a significant healthcare burden in terms of hospital resources, morbidity, and mortality. Primary prevention and early detection of risk factors for the development of CHD are pivotal to successful intervention programs and prognostication. Yet, there remains a paucity of evidence regarding differences in the assessment of these risk factors and the tools of assessment among different ethnicities. We conducted a narrative review to assess the utility of cardiac computed tomography, particularly coronary artery calcification (CAC), in different ethnicities. We also looked to see whether age, sex, comorbidities, and genetic background have peculiar influences on CAC. In this review, we highlight some of the pivotal studies regarding the question of CAC in relation to the development of CHD among different ethnicities. We identify several key trends in the literature showing that although African Americans have high rates of CHD, their risk of CAC may be relatively lower compared with other ethnicities. Similarly, South Asian patients may be at a high risk for adverse cardiac events due to elevated CAC. We also note that several studies are limited by small sample size and were based on 1 large cohort study. Future studies should include a large international prospective cohort to truly evaluate the effects of ethnicity on CAC and CHD risk. To appropriately apply CAC in the clinical practice, the variations in its scoring based on a subject's age, sex, comorbidity, and ethnicity should be addressed and interpreted beforehand.

23 Review The Year in Vascular Anesthesia: Selected Highlights From 2017. 2018

Valentine, Elizabeth A / Zhou, Elizabeth Y / Gordon, Emily K / Ochroch, E Andrew. ·Department of Anesthesiology and Critical Care, Division of Cardiovascular and Thoracic Anesthesiology, Hospital of the University of Pennsylvania, Philadelphia, PA. Electronic address: elizabeth.valentine@uphs.upenn.edu. · Department of Anesthesiology and Critical Care, Division of Cardiovascular and Thoracic Anesthesiology, Hospital of the University of Pennsylvania, Philadelphia, PA. ·J Cardiothorac Vasc Anesth · Pubmed #29784496.

ABSTRACT: -- No abstract --

24 Review Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: Where Are We Now? 2018

D'Angelo, Ryan G / McGiness, Thaddeus / Waite, Laura H. ·1 University of the Sciences-Philadelphia College of Pharmacy, Philadelphia, PA, USA. · 2 Hospital of the University of Pennsylvania, Philadelphia, PA, USA. ·Ann Pharmacother · Pubmed #29577768.

ABSTRACT: OBJECTIVE: To synthesize the literature and provide guidance to practitioners regarding double therapy (DT) and triple therapy (TT) in patients with atrial fibrillation (AF) requiring percutaneous coronary intervention (PCI). DATA SOURCES: PubMed and MEDLINE (January 2000 to February 2018) were searched using the following terms: atrial fibrillation, myocardial infarction, acute coronary syndrome, percutaneous coronary intervention, anticoagulation, dual-antiplatelet therapy, clopidogrel, aspirin, ticagrelor, prasugrel, and triple therapy. STUDY SELECTION AND DATA EXTRACTION: The results included randomized and nonrandomized clinical trials and meta-analyses. Each study was reported based on study design, population, intervention, comparator, and key cardiovascular (CV) and bleeding outcomes. DATA SYNTHESIS: A total of 15 studies were included in the review. The majority of studies evaluating DT and TT utilized clopidogrel and warfarin as components of the regimen, although there are emerging data with newer agents. Evidence purporting DT regimens to be equally effective in preventing CV events and improved safety profiles compared with TT regimens included populations with relatively low risk for recurrent CV events, and many of these studies were observational in nature. Overall, current evidence as well as American and European guidelines support the use of TT in patients with AF who require PCI for the least possible amount of time, depending on patient-specific factors involving bleeding and thrombosis. CONCLUSIONS: In the majority of patients with AF who require PCI, TT should be used for the shortest period of time possible. DT regimens may be used in patients requiring PCI who have low risk for thrombosis and/or high bleeding risk.

25 Review Angiopoietin-like protein 4: A therapeutic target for triglycerides and coronary disease? 2018

Olshan, David S / Rader, Daniel J. ·Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. Electronic address: david.olshan@uphs.upenn.edu. · Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. ·J Clin Lipidol · Pubmed #29548670.

ABSTRACT: The angiopoietin-like proteins are a family of proteins that share structural similarities to the angiopoietins. These proteins have been described to play a key role in the regulation of a myriad of physiologic processes, including serving as essential modulators of lipid and glucose metabolism. Angiopoietin-like protein 4 (ANGPTL4) is a key regulator of lipoprotein lipase, and its modulation has been shown to significantly impact the body's processing and distribution of triglycerides and cholesterol. Although more research remains to elucidate the full range of mechanisms through which ANGPTL4 affects triglyceride and cholesterol homeostasis, current research has associated decreased ANGPTL4 function with a beneficial effect on lipid parameters and overall cardiovascular disease risk, opening the possibility of ANGPTL4 as a new therapeutic target for the treatment of cardiovascular disease.

Next